VALBIOTIS SA (ALVAL.PA) Stock Price, Forecast & Analysis
EPA:ALVAL • FR0013254851
ALVAL.PA Key Statistics, Chart & Performance
The current stock price of ALVAL.PA is 1.094 EUR. In the past month the price increased by 56.29%. In the past year, price decreased by -17.12%.
ALVAL.PA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ALVAL.PA. When comparing the yearly performance of all stocks, ALVAL.PA is one of the better performing stocks in the market, outperforming 93.91% of all stocks.
ALVAL.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALVAL.PA. While ALVAL.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
ALVAL.PA Financial Highlights
Over the last trailing twelve months ALVAL.PA reported a non-GAAP Earnings per Share(EPS) of -0.7. The EPS decreased by -7.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -55.87% | ||
| ROE | -94.6% | ||
| Debt/Equity | 0.25 |
ALVAL.PA Forecast & Estimates
11 analysts have analysed ALVAL.PA and the average price target is 2.18 EUR. This implies a price increase of 98.9% is expected in the next year compared to the current price of 1.094.
For the next year, analysts expect an EPS growth of 33.86% and a revenue growth 375% for ALVAL.PA
ALVAL.PA Ownership
ALVAL.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| 1AE | ARGENX SE | 27.86 | 43.529B | ||
| ARGX | ARGENX SE | 27.84 | 43.504B | ||
| 22UA | BIONTECH SE-ADR | N/A | 21.617B | ||
| ABVX | ABIVAX SA | N/A | 8.158B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.868B | ||
| GLPG | GALAPAGOS NV | N/A | 1.866B | ||
| 6IV | INVENTIVA SA | N/A | 1.034B | ||
| IVA | INVENTIVA SA | N/A | 1.008B | ||
| NANO | NANOBIOTIX | N/A | 994.371M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About ALVAL.PA
Company Profile
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 44 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Company Info
VALBIOTIS SA
12F rue Paul Vatine
Perigny NOUVELLE-AQUITAINE FR
Employees: 44
VALBIOTIS SA / ALVAL.PA FAQ
What does ALVAL do?
Valbiotis SA engages in the products and candidate drugs designed to prevent metabolic diseases. The company is headquartered in Perigny, Nouvelle-Aquitaine and currently employs 44 full-time employees. The company went IPO on 2017-06-07. The firm specializes in developing nutrition solutions designed to prevent cardiometabolic diseases and provide nutritional support for patients. The company seeks to develop solutions designed to prevent type 2 diabetes, NASH, (non-alcoholic steatohepatitis) and obesity and to offer nutritional support. The firm prevents disease by developing products that reduce the risk factors of irreversible chronic diseases. The company provides patient support through new-generation medical nutrition solutions containing patented substances with clinically proven effects. Its products are plant-based and undergo strict scientific and clinical tests in collaboration with academic research centers.
Can you provide the latest stock price for VALBIOTIS SA?
The current stock price of ALVAL.PA is 1.094 EUR. The price increased by 0.37% in the last trading session.
Does ALVAL stock pay dividends?
ALVAL.PA does not pay a dividend.
How is the ChartMill rating for VALBIOTIS SA?
ALVAL.PA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for ALVAL stock?
VALBIOTIS SA (ALVAL.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.7).
Can you provide the growth outlook for VALBIOTIS SA?
The Revenue of VALBIOTIS SA (ALVAL.PA) is expected to grow by 375% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Can you provide the upcoming earnings date for VALBIOTIS SA?
VALBIOTIS SA (ALVAL.PA) will report earnings on 2026-03-02, after the market close.